Among mortality in patients with HF, SGLT2 inhibitors with low SGLT2/SGLT1 selectivity may be beneficial for reducing all-cause mortality, but only inhibitors with high selectivity for reducing CV death. This evidence concerns the gene SLC5A2 and hydrops fetalis.